Using sequences from m909, we previously created an FRβ targeted CAR T cell approach that demonstrated activity in both in vitro and in vivo models of AML without evidence of hematopoietic stem cell toxicity [28,29]. Here, FOLR2 is linked to acute myeloid leukemia.